Trials / Recruiting
RecruitingNCT06842186
A Phase 1 Study of WVE-007 in Adults Living With Overweight or Obesity
A Phase 1, Randomized, Double-blind, Placebo-controlled Study of Ascending Doses of WVE-007 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Adults Living With Overweight or Obesity
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 136 (estimated)
- Sponsor
- Wave Life Sciences Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of WVE-007 when administered subcutaneously (SC) as single ascending doses in adults who are affected by overweight or obesity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | WVE-007 | Stereopure siRNA oligonucleotide |
Timeline
- Start date
- 2025-01-31
- Primary completion
- 2026-10-01
- Completion
- 2026-10-01
- First posted
- 2025-02-24
- Last updated
- 2026-02-10
Locations
6 sites across 4 countries: United States, Moldova, Romania, United Kingdom
Source: ClinicalTrials.gov record NCT06842186. Inclusion in this directory is not an endorsement.